logo
Book a meeting
Thrombolytic Science

Thrombolytic Science

Biotechnology, 763d Concord Ave, Cambridge, Massachusetts, 02138, United States, 1-10 Employees

tsillc.net

  • twitter
  • LinkedIn

phone no Phone Number: +16*********

Who is THROMBOLYTIC SCIENCE

TSI is a privately-held vascular medicine and biotechnology company currently developing a new-generation clot-dissolving therapy with the first novel mechanism of action in 20 years for ...

Read More

lock icon Get Full Access
map
  • 763d Concord Ave, Cambridge, Massachusetts, 02138, United States Headquarters: 763d Concord Ave, Cambridge, Massachusetts, 02138, United States
  • 2006 Date Founded: 2006
  • 1-10 Employees: 1-10
  • dollar-icon Revenue: $1 Million to $5 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 2834 | NAICS Code: 541720 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from THROMBOLYTIC SCIENCE

Thrombolytic Science Org Chart and Mapping

Employees
Victor Gurewich

Victor Gurewich

Physician, Professor of Medicine, Harvard Medical School

See Full Org Chart arrow
email-formate-icon
View Email Formats for Thrombolytic Science
arrow
signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

Join Now

crown-icon Free credits every month

Frequently Asked Questions Regarding Thrombolytic Science

Answer: Thrombolytic Science's headquarters are located at 763d Concord Ave, Cambridge, Massachusetts, 02138, United States

Answer: Thrombolytic Science's phone number is +16*********

Answer: Thrombolytic Science's official website is https://tsillc.net

Answer: Thrombolytic Science's revenue is $1 Million to $5 Million

Answer: Thrombolytic Science's SIC: 2834

Answer: Thrombolytic Science's NAICS: 541720

Answer: Thrombolytic Science has 1-10 employees

Answer: Thrombolytic Science is in Biotechnology

Answer: Thrombolytic Science contact info: Phone number: +16********* Website: https://tsillc.net

Answer: TSI is a privately-held vascular medicine and biotechnology company currently developing a new-generation clot-dissolving therapy with the first novel mechanism of action in 20 years for stroke and other thrombotic diseases. TSIs technology is based upon pioneering earlier work on pro-urokinase (proUK) by its cofounders. The primary component of TSIs thrombolytic therapy is a rationally designed mutant of proUK.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access